Review article

Paediatric brain tumours: A review of radiotherapy, state of the art and challenges for the future regarding protontherapy and carbontherapy

Tumeurs cérébrales pédiatriques : revue de la littérature en radiothérapie, état de l’art et défis pour l’avenir en ce qui concerne la protonthérapie et la carbonthérapie

A. Laprie,²,b,c, Y. Hu,² C. Alapetite,² C. Carrie,²,k J.-L. Habrand,²,g,h,i,j S. Bolle,²,k, P.-Y. Bondiau,²,m A. Ducassou,²,b,c A. Huchet,²,h A.-L. Bertozzi,²,c,o, Y. Perel,² É. Moyal,²,b,c J. Balosso,²,d,p, on behalf of the radiotherapy committee of SFCE and France Hadron¹

¹Université Paul-Sabatier, Toulouse, France
²Institut Claudius-Regaud, institut universitaire du cancer de Toulouse (IUCT)-Oncopole, radiation oncology, 1, avenue Irene-Joliot-Curie, 31059 Toulouse, France
³Péri­cî­ë­s-France-Hadron, Toulouse, France
⁴GCS-Étoile-France-Hadron, Lyon, France
⁵Institut Curie Paris Orsay (ICPO)-France-Hadron, Orsay, France
⁶Centre Leon-Bérard, Lyon, France
⁷Université Paris Sud, Orsay, France
⁸Archade-France-Hadron, Caen, France
⁹Centre François-Baclesse, Caen, France
¹⁰Gustave-Roussy, Villejuif, France
¹¹Impact-France-Hadron, Nice, France
¹²Centre Antoine-Lacassagne, Nice, France
¹³CHU de Bordeaux, Bordeaux, France
¹⁴Hôpital des Enfants, Toulouse, France
¹⁵Université Grenoble Alpes, Grenoble, France
¹⁶CHU de Grenoble, Grenoble, France

A R T I C L E  I N F O

Article history:
Received 17 December 2014
Received in revised form 18 May 2015
Accepted 21 May 2015

Keywords:
Paediatric brain tumour
Protontherapy
Carbontherapy
Ependymoma
Craniopharyngioma
Medulloblastoma
Craniospinal irradiation
Germ-cell tumours

A B S T R A C T

Background and purpose. — Brain tumours are the most frequent solid tumours in children and the most frequent radiotherapy indications in paediatrics, with frequent late effects: cognitive, osseous, visual, auditory and hormonal. A better protection of healthy tissues by improved beam ballistics, with particle therapy, is expected to decrease significantly late effects without decreasing local control and survival. This article reviews the scientific literature to advocate indications of protontherapy and carbon ion therapy for childhood central nervous system cancer, and estimate the expected therapeutic benefits.

Materials and methods. — A systematic review was performed on paediatric brain tumour treatments using Medline (from 1966 to March of 2014). To be included, clinical trials had to meet the following criteria: age of patients 18 years or younger, treated with radiation, and report of survival. Studies were also selected according to the evidence level. A secondary search of cited references found other studies about cognitive functions, quality of life, the comparison of photon and proton dosimetry showing potential dose escalation and/or sparing of organs at risk with protontherapy; and studies on dosimetric and technical issues related to protontherapy.

Results. — A total of 7051 primary references published were retrieved, among which 40 clinical studies and 60 papers about quality of life, dose distribution and dosimetry were analysed, as well as the ongoing clinical trials. These papers have been summarized and reported in a specific document made available to

* Corresponding author.
E-mail address: laprie.anne@iuct-oncopole.fr (A. Laprie).
¹SFCE : Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (French society of childhood cancers).

http://dx.doi.org/10.1016/j.canrad.2015.05.028
1278-3218/© 2015 Published by Elsevier Masson SAS on behalf of the Société française de radiothérapie oncologique (SFRO).
the participants of a final 1-day workshop. Tumours of the meningeal envelop and bony cranial structures were excluded from the analysis. Protontherapy allows outstanding ballistics to target the tumour area, while substantially decreasing radiation dose to the normal tissues. There are many indications of proton-therapy for paediatric brain tumours in curative intent, either for localized treatment of ependymomas, germ-cell tumours, craniohypophysial, low-grade gliomas; or panventricular irradiation of non-secreting germinoma; or craniospinal irradiation of medulloblastomas and metastatic pure germinomas. Carbon ion therapy is just emerging and may be studied for highly aggressive and radioresistant tumours, as an initial treatment for diffuse brainstem gliomas, and for relapse of high-grade gliomas.

Conclusion. – Both protontherapy and carbon ion therapy are promising for paediatric brain tumours. The benefit of decreasing late effects without altering survival has been described for most paediatric brain tumours with protontherapy and is currently assessed in ongoing clinical trials with up-to-date proton devices. Unfortunately, in 2015, only a minority of paediatric patients in France can receive protontherapy due to the lack of equipment.

© 2015 Published by Elsevier Masson SAS on behalf of the Société française de radiothérapie oncologique (SFRO).

RÉSUMÉ

Objectifs. – Les tumeurs cérébrales sont l’indication de radiothérapie pédiatrique la plus fréquente, avec des effets tardifs fréquents : cognitifs, osseux, visuels, auditifs et hormonaux. En raison de leur balistique exceptionnelle, les faisceaux de particules pourraient apporter une meilleure protection des tissus sains sans diminuer le contrôle local et la survie. Cet article est une revue de la littérature scientifique ayant pour but de proposer les indications de protonthérapie et de thérapie par ions carbone pour les tumeurs cérébrales pédiatriques et d’estimer les bénéfices thérapeutiques escomptés.

Matériel et méthodes. – Une revue systématique a été réalisée sur les essais cliniques de radiothérapie des tumeurs pédiatriques en utilisant Medline (de 1986 à mars 2014), selon les critères suivants : patients âgés de 18 ans ou moins, ayant reçu une radiothérapie et comportant des données de survie. Les études sur les fonctions cognitives, la qualité de vie, la comparaison dosimétrique photons–protons ont également été inclues.

Résultats. – Sur 7051 références primaires publiées, 40 études cliniques et 60 articles de qualité de la vie et dosimétrie ont été analysés, ainsi que les essais cliniques en cours. Ces documents ont été condensés et présentés dans un document spécifique mis à la disposition des experts participant à un atelier final d’une journée. Il existe de nombreuses indications de protonthérapie pour les tumeurs cérébrales pédiatriques à visée curative : pour le traitement localisé des ependymomes, tumeurs germinales, craniopharyngiomes, gliomes de bas grade, pour l’irradiation pan-ventriculaire des germinomes purs non-sécrétant et pour l’irradiation crâniospinale des médulloblastomes et germinomes purs métastatiques. La thérapie par ions carbone est en train d’émerger et pourrait être étudiée pour les tumeurs très agressives et radiorésistantes, tels les gliomes du tronc cérébral diffus, et les récurrences des gliomes de haut grade.

Conclusion. – Pour les tumeurs cérébrales pédiatriques, protonthérapie et thérapie par ions carbone sont prometteuses. L’avantage de diminuer les effets tardifs sans altérer la survie a été décrit pour la plupart des tumeurs cérébrales pédiatriques avec la protonthérapie et est en évaluation dans des essais cliniques en cours. Actuellement, en France, une minorité de patients pédiatriques reçoit une protonthérapie en raison du manque d’équipement.

© 2015 Publié par Elsevier Masson SAS pour la Société française de radiothérapie oncologique (SFRO).

1. Introduction

1.1. Radiotherapy for pediatric brain tumours

Brain tumours are the most frequent paediatric solid tumours in children. In most cases, treatment includes surgery and radiotherapy with or without chemotherapy. Paediatric brain tumours acutely raise the question of treatments long-term tolerance. According to paediatric brain tumour natural history, the treatment is either addressing the general spreading of the disease or the local invasion and often both. Whenever the local control is the upfront challenge for the cure rate, the role of surgery and radiation therapy is important. The main drawback of radiation therapy is its acute and late toxicity that are particularly serious for central nervous system in childhood. Intelligence quotient impairment and other functional loss are well-documented. The challenge is therefore to improve the local control with less toxicity by identifying very accurately the target and avoiding irradiation of normal tissues outside the target.

Although surgery could be improved by postoperative assessment and sophisticate imaging, more improvement could come from altered radiotherapy technics as particle therapy. Actually, the better dose localization of particle therapy opens the possibility to increase target dose and to decrease organs at risk dose in the same time. Even more, in case of really very radioresistant tumours, heavy ions could be used with the same possibility of organs at risk sparing. Actually, protontherapy is a highly conformal treatment, able to reduce the absorbed dose to the normal brain parenchyma, the optic pathways, hypothalamus and sensorial organs.

However, one should consider also the risk of undue relapses while changing from larger integrated dose with photons to more localized dose of protons, due to uncertainties of the microscopic extend of the disease [1]. Similarly, uncertainties are remaining about the relative biological efficiency of particle therapy especially for children normal brain, and for tumours.

Thus, a complex figure of multiple parameters is existing in the domain of paediatric tumours including pattern of spreading and relapse, targets nature and location, tumour sensitivity, age of the patients, side-effects risk, that are influencing the possibilities of improvement by the use of particle therapy.

In France, presently, there is only one high-energy proton-therapy center (ICPO, Orsay) able to treat such tumours [2]. The
other French protontherapy center (Impact/Médicyc, Nice) is getting upgraded to access high energy, and there are several other projects. There is a need to determine how many regional referral centres, equipped with such technique, are necessary in France. An analysis of all indications for adults and children must be performed. This prompted the radiotherapy committee of the French society of childhood cancers (Société française de lutte contre les cancers et les leucémies de l'enfant et de l'adolescent [SFCE]), to join the France Hadron consortium to define the indications of particle therapy for paediatric brain tumours. The France Hadron consortium includes existing particle therapy centres (ICPO in Orsay and Impact/Médicyc in Nice), as well as projects (centre Étoile in Lyon, Archade in Caen, Périclès in Toulouse).

The present paper reviews the toxicity and impairment data regarding paediatric central nervous system tumours, then details, for each type of paediatric brain tumours, the present challenges, the contribution of radiotherapy as a treatment component and the possibilities to improve it including by the use of particle therapy, and, how to assess this by evidence-based medicine approaches.

1.2. Late effects of paediatric cerebral radiation therapy

Cognitive dysfunction and endocrinopathy are the most frequent side effects of brain radiation therapy. Depending on tumour location; auditory and visual impairment are also frequent. Vascularopathy with stroke and second cancers are much less frequent.

Additionally, in case of intraspinal irradiation, decreased bone growth is constant, risks on lung and heart function do exist [3–5].

Moreover, the use of anticancer agent is a cause of second cancer.

2. Methods

Prior to the literature research, an expert group identified the potential indications for hadrontherapy (proton and carbon) in terms of tumour location and/or histology according to basic principle. These principles were: radioresistant unresectable tumours surrounded by organ at risk, with mainly local–regional spreading for patients lacking heavy comorbidities.

The Medline database and Cochrane Library (from January 1966 to March 2014) were used to perform the search. The query equation was made of combinations of tumours and treatments names: “paediatric/childhood”, “central nervous system cancer” (including all brain tumour types), and “radiotherapy” (including all types of radiotherapy). Tumours of the meningeal envelopes and bony cranial structures have been excluded from the analysis.

Only papers in English were considered and then selected on their titles and abstracts; a second selection was done by reading the full papers. To be included, clinical trials had to meet the following criteria: patient’s median age 18 years or less, patients receive a radiotherapy, and the study reported survival results, relevant clinical outcomes, and substantial duration of follow-up. Furthermore, to be compared with photon, dosimetric studies were also included in this analysis. Because of the childhood population, papers about cognitive function and quality of life were included. When several papers were related to the same study, only the most recent one has been used. Clinical studies were selected according to their levels of evidence (randomized controlled trials > controlled trials > non-controlled observation trials). The information collected was: study design, patients’ characteristics, radiation modality, radiation dose and fraction, and patient outcomes. The primary endpoint was local control. The secondary endpoints were overall survival and late toxicity.

As a whole, 7051 primary references were retrieved among which 40 report on clinical studies and 60 papers about quality of life, dose distribution and dosimetry were analysed, as well as the descriptions of the ongoing clinical trials. These papers have been summarized and reported in a specific document made available to the participants of a final 1-day workshop. The literature review has been summarized in a report submitted to a group of experts on brain tumours, and then proton and carbon radiotherapy indications have been discussed during a 1-day workshop whose conclusions are the base of the present paper.

3. Results

3.1. Gliomas

Glioma, according to their pathological grade and anatomical location, are of different level of life-threatening seriousness which is described thereafter (Table 1). Low-grade gliomas are the most commonly diagnosed brain tumour in children and the most common cause of child brain irradiation. The overall survival rate being rather good, the main concern is the treatment related late toxicity, which justifies the search for alternatives to the use of radiotherapy.

High-grade glioma are rare in children but have a very poor prognosis [10,11]. They are very infiltrative needing large volume to treat and consequently represent poor indication for radiation therapy, although applied on a regular basis.

3.1.1. Optic pathway glioma

Optic pathway gliomas represent 1–5% of all gliomas in childhood. These low-grade gliomas are associated with type 1 neurofibromatosis (NF1) in 18–70% of cases. They differ in their natural history according to their location along the optic tract. As long as there is no clinical or imaging progression, follow-up is just recommended. When neurosurgery is done for distal location of tumours, it results in blindness of the involved eye. However, in case of chiasmatic or proximal location, surgery would lead to unacceptable side effects; therefore, radiation therapy is recommended (Fig. 1).

Radiation therapy proved to improve local control and relapse-free survival [7]. A recent study, which compared protontherapy versus 3D-photon radiation therapy, showed that protontherapy offered a high degree of conformity to target volumes and substantial normal-tissue sparing in both high and low-dose areas. Advantages of protontherapy versus 3D-photon radiation therapy are increasingly apparent with increasing target size and tumour complexity. However, the indication for radiation therapy remains limited to symptomatic tumour growth. Another approach could be to broaden the use of protontherapy to earlier cases to treat smaller volumes, as suggested by a study reporting lower risks of visual loss with upfront photon radiation therapy compared with post-cemoradation therapy [12]. Protontherapy, being safer than photon radiation therapy, its earlier use should allow better visual protection [6].

3.1.2. Low-grade glioma

Low-grade gliomas account for 30% to 50% of paediatric brain tumours and can occur at all ages. Surgery alone may be curative, but radiation therapy will ultimately be required for most patients, especially when the tumour is central, and involves the diencephalon and optic pathways. The overall survival rate, when complete resection, are around 80% to 90% at 10 years. The long-term cumulative risks of radiation therapy late effects have
promoted the search for alternatives to reduce the long-term side effects for children. However, the tremendous progress of radiotherapy in the last decade justifies studies to reassess the benefit of radiation therapy.

Fig. 1. Radiotherapy of optic pathways glioma in a child: 52.2 Gy given to both optic pathways; dose constraints to posterior and anterior parts of the eye were respected. The dose delivered to a part of the temporal lobes was a median of 10 Gy. Courtesy of Dr S. Bolle, centre de protonthérapie d’Orsay.

3.1.2.1. Published studies on radiation therapy for low-grade gliomas. Two recent studies, based on prospective trials in two different institutions, confirmed the hypothesis that irradiation with only 10 mm of clinical target volume (CTV) margin did not affect the rate of treatment failure in paediatric low-grade gliomas [8,13]. This decreased planning target volume (PTV) may reduce the cognitive effects [14]. Furthermore, it is now considered that the CTV margin could be further reduced to 5 mm. Another result is that the 4% rate of vasculopathy is even more important in young children and in patients with a type-1 neurofibromatosis (NF1) [7]. Another study, from the same authors, shows that the cognitive effects of radiation therapy correlated with the patient’s age, NF1 status, tumour location and volume, extent of resection, and radiation dose [15]. The effect of age exceeded that of radiation dose, with patients younger than 5 years experiencing the greatest decline in cognition.

A retrospective study of proton therapy for low-grade gliomas has shown the safety and efficacy of this technique, making low-grade glioma a potentially good indication of proton therapy when radiation therapy is needed, especially in cases of large (more than 4 cm) or complex volumes, and in cases of close proximity to sensitive structures [9]. However, caution is needed for baseline evaluation and follow-up, and it should be noted that NF1 patients’ (25% of low-grade gliomas) appear to have a higher baseline rates of vasculopathy, and that children before 5 years old are more radiosensitive.

3.1.2.2. Ongoing studies on radiation therapy for low-grade gliomas. A large COG phase II study of conformal radiotherapy in patients with low grade gliomas, with reduced margins using photons or protons, is described at: http://clinicaltrials.gov/ct2/show/NCT00238264?term=astrocytoma&recr=Open&��nt=radiothera my&out=survival&age=0&rank=3.

Event-free survival was designed as the primary endpoint, and quality of life is also assessed.
3.1.3. High-grade glioma

High-grade gliomas represent approximately 10% of all paediatric brain tumours. They are very infiltrative; thus treatment volumes have to be very large. Their prognosis is very poor despite a variety of therapies including chemotherapy and radiotherapy (Table 1) [10,11]. High-grade glioma is one of the leading causes of cancer-related deaths in children with a current 2-year survival rate of 10–30% [16]. Whenever possible, children undergo surgery followed by radiation therapy with chemotherapy. External radiation therapy targeting the resected site of the tumour has been shown to improve survival when compared to surgery alone, and it is therefore considered as the standard of care.

3.1.3.1. Published studies on radiation therapy for high-grade gliomas. Combs et al. described, in-vitro, that high linear energy transfer (LET) carbon-ion irradiation was significantly more effective at destroying glioblastoma cell lines compared to photon irradiation; this as quoted to the due to the high relative biological efficiency of carbon ions [17].

Since patients experience frequent in-field incurable relapses, it could be of interest to test carbon ions therapy for re-irradiation of limited volumes. Treatment of patients with recurrence includes surgery, chemotherapy, or re-irradiation. Re-irradiation needs to be done with caution, but has improved survival in adult studies [18]. As carbon ions offer optimal delivery within the spread of the Bragg peak, a prospective phase III trial, named Cinderella, is currently ongoing that includes adult patients receiving carbon re-irradiation for high-grade gliomas [19]. Depending on the results of this study, this approach could be applied to children. Because of the large volumes to be irradiated and the poor survival rates, high-grade glioma is not a primary indication for protontherapy.

3.1.3.2. Ongoing studies on treatments for high-grade gliomas. To date, there are, on the NCI site, many (approximately 20) phases I and II ongoing studies of targeted drugs associated with radiotherapy in children with diffuse intrinsic pontine gliomas and high grade gliomas, but no protontherapy trial are ongoing for these tumours: http://clinicaltrials.gov/ct2/results?term=high-grade+glioma+paediatric&Search.

3.1.4. Diffuse intrinsic pontine gliomas

Diffuse intrinsic pontine gliomas represent 80% of paediatric brainstem gliomas and ~10% of all paediatric brain tumours. Following radiation therapy, which is the main treatment, the majority of patients improve clinically. However, diffuse intrinsic pontine glioma carries a bleak prognosis as the progression-free interval is usually shorter than 6 months and survival is poor, with median survival times of less than 1-year and 2-year survival rates < 20%. Many new therapies have been evaluated for diffuse intrinsic pontine gliomas over the last 2 decades, including radiation-dose escalation with hyperfractionated- or accelerated radiation therapy, pre-irradiation chemotherapy, high-dose chemotherapy and new radiosensitizers [20–25]. Unlike other types of paediatric brain tumours, little progress has been made in the treatment of diffuse intrinsic pontine gliomas [26]. Therefore, there is a need for new paradigms of treatment [27]. The ballistics of proton therapy would not bring benefit for dose escalation and the lesser risk of late effects cannot be expected for these children. Carbon ion therapy, due to its higher relative biological efficiency, should be tested in this radiosensitive tumour. There are scarce data, but a recent article concluded that particle therapies for skull-based tumours produced minimal symptomatic brain toxicities [28]. We propose to perform a phase I–II trial on carbon ion therapy dose-escalation, with a target dose of 60 Gy (ISO E, the relative biological efficiency of protons, considered as 1.1), a hypofractioned approach could be considered.

3.2. Primitive neuroectodermal tumours (PNET)

3.2.1. Medulloblastoma

Medulloblastoma is a primitive neuro-ectodermal tumour (PNET) arising in the cerebellum or the fourth ventricle. It causes the second highest incidence of paediatric tumours (20%) with the mean incidence age of 6 years. The treatment approaches are decided according to age and risk criteria. Risk factors, such as age, quality of resection, metastatic extent, histopathology, cytogenetic and molecular factors, are used for the classification of the tumour [29].

3.2.1.1. Published studies on the treatment of medulloblastomas. Craniospinal irradiation is part of the standard treatment for this disease because of the high risk of leptomeningeal spread. Depending on the risk level, either 24 or 36 Gy are delivered to the craniospinal axis, followed by a boost to the primary site and to the metastatic sites, if existing [4,19,30,31] (Table 2). Children under the age of 3 to 5 years are usually treated with surgery followed by intensive chemotherapy to delay radiation therapy. Using such treatment, more than 60% of standard-risk patients (no metastatic disease and no gross residual disease after surgery, favourable histology, and molecular biology) can be cured, but the resulting morbidity can often be high especially regarding cognitive function, altered bone growth, and hormonal deficits.

A dosimetry study published by Saint-Clair et al., in 2004, compared treatments using radiation therapy, intensity-modulated radiation therapy or protontherapy on craniospinal axis irradiation with a posterior fossa boost, in a patient with medulloblastoma [42]. The paper described substantial normal-tissue sparing, mainly cochlea and heart, with intensity-modulated radiation therapy, and even more with protontherapy compared with the conventional radiation therapy. Because of the finite range of proton beams, heart exposure is much lower and cardiac toxicity would be substantially reduced as well as other toxicities to any anterior thoracic structures [4]. Moreover, the higher conformation of the boost delivered, after craniospinal, to the posterior fossa with protons spares the supratentorial brain, particularly the temporal lobes, and the cochlea, this will limit cognitive impairment and hearing loss, as well as avoiding to increase the dose to the pituitary gland, without which is not possible with conformal- or intensity-modulated radiation therapy; this might limit growth hormone disorders and other anterior pituitary deficits.

A recent paper describes the results of protontherapy for medulloblastoma and supratentorial PNET in very young children, which resulted in good disease outcome and low toxicity rates [41]. A point–counterpoint controversy about this approach has been published in a recent issue of the same journal balancing clinical data versus ethical issues for medulloblastoma protontherapy [13]. One side concluded that based on dosimetric studies and emerging clinical evidences, protontherapy is the only ethical approach, whereas the other one questioned the burden of displacement for treatment and emphasized the need for appropriate timing [13,43]. But both sides concluded that all patients should at least be offered a referral for protontherapy in case of medulloblastoma.

There was, up to now, a concern regarding the pattern of failure that may differ because of the steeper dose gradients with protontherapy. A recent paper by the Massachusetts General Hospital on 109 patients gave the pattern of the 16 patients that relapsed and they did not seem to differ from those of patients treated with photon therapy [37].
Table 2
Published studies on the treatment of medulloblastomas in children.

<table>
<thead>
<tr>
<th>Study</th>
<th>Scheme/Protocol</th>
<th>Treatment</th>
<th>Radiotherapy</th>
<th>Chemotherapy</th>
<th>Number of patients</th>
<th>Overall survival</th>
<th>Event-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Proton</td>
<td>Photon</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard risk medulloblastomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taylor et al., 2004 [32]</td>
<td>Chemoradiotherapy</td>
<td>Radiotherapy</td>
<td>–</td>
<td></td>
<td>90</td>
<td>3-year: 79.5 %</td>
<td>3-year: 71.6 %</td>
</tr>
<tr>
<td>Merchant et al., 2008 [33]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>87</td>
<td>5-year: 70.7 %</td>
<td>5-year: 67.0 %</td>
</tr>
<tr>
<td>Packer et al., 2006 [34]</td>
<td>Chemoradiotherapy</td>
<td>–</td>
<td></td>
<td></td>
<td>136</td>
<td>3-year: 73.8 %</td>
<td>5-year recurrence-free survival: 64.8 %</td>
</tr>
<tr>
<td>Oyharcabal-Bourden et al., 2005 [35]</td>
<td>Chemoradiotherapy</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carrie et al., 2009 (MSFOP 98) [3]</td>
<td>Hyperfractionated radiotherapy</td>
<td>Standard radiotherapy</td>
<td>–</td>
<td></td>
<td>70</td>
<td>11 relapses (median follow-up 38 months)</td>
<td></td>
</tr>
<tr>
<td>Lannering et al., 2012 (PNET4 trial) [36]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>3-year: 89%</td>
<td>6-year: 75%</td>
</tr>
<tr>
<td>Sethi et al., 2014 [37]</td>
<td>St-Jude medulloblastoma-96</td>
<td>–</td>
<td></td>
<td></td>
<td>68</td>
<td>3-year: 50%</td>
<td>5-year: 44%</td>
</tr>
<tr>
<td>Gajjar et al., 2006 [30]</td>
<td>PNET-3</td>
<td>–</td>
<td></td>
<td></td>
<td>115</td>
<td>3-year: 68%</td>
<td>5-year: 60%</td>
</tr>
<tr>
<td>Taylor et al., 2005 [38]</td>
<td>SFOP TC 04/94</td>
<td>–</td>
<td>36 Gy + boost 18 Gy</td>
<td></td>
<td>28</td>
<td>5-year: 50%</td>
<td>5 relapses (median follow-up 38 months)</td>
</tr>
<tr>
<td>Verloo et al., 2006 [39]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>70</td>
<td>11 relapses (median follow-up 38 months)</td>
<td></td>
</tr>
<tr>
<td>Sethi et al., 2014 [37]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>3-year: 75%</td>
<td>5-year: 70%</td>
</tr>
<tr>
<td>Grill et al., 2005 [31]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>68</td>
<td>3-year: 40%</td>
<td>5-year: 35%</td>
</tr>
<tr>
<td>Rutkowski et al., 2005 [40]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>115</td>
<td>3-year: 54%</td>
<td>5-year: 50%</td>
</tr>
<tr>
<td>Jimenez et al., 2013 [41]</td>
<td>–</td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td>5-year: 50%</td>
<td>5 relapses (median follow-up 38 months)</td>
</tr>
</tbody>
</table>

Medulloblastomas of young children (< 3 years old)

Grill et al., 2005 [31] | – | Salvage treatment | Carboptatin, procarbazine, etoposide, cisplatin, vincristine, cyclophosphamide and uromitexan | 79 | 5-year R0M0: 73% | 5-year R0M0: 29% |
| Rutkowski et al., 2005 [40] | – | Salvage treatment | Carboptatin, procarbazine, etoposide, cisplatin, vincristine, cyclophosphamide and uromitexan | 43 | 5-year: 66 ± 7 % | 5-year: 58 ± 9% |
| Jimenez et al., 2013 [41] | – | Ceiling irradiation 21 Gy, boost 54 Gy (relative biological efficiency) | High dose chemotherapy | 12 | 11 alive at median follow-up of 39 months | 1 non-disease related death |
### 3.2.1.2. Ongoing studies on the treatment of paediatric medulloblastoma

There is one ongoing study of protons for paediatric medulloblastoma: proton beam radiotherapy for medulloblastoma and pinealoblastoma: an assessment of acute toxicity and long term neurocognitive, neuroendocrine and otoxicity outcomes NCT01063114 (http://clinicaltrials.gov/ct2/show/NCT01063114?term=proton+medulloblastoma&rank=1). This observational monocentric study includes patients between 3 and 25 years of age. The three primary outcome measures are otoxicity, endocrine dysfunction and neurocognitive effects.

**Recommendations**

As a whole, we would strongly suggest:

- the use of protontherapy for craniospinal irradiation in children;
- for adolescents and young adults, whatever the disease stage, to establish the bone age and then, if growth is complete, to treat only the spinal canal, with safety margins.

### 3.2.2. Supratentorial PNET

Supratentorial primitive neuroectodermal tumours (SPNET) accounts for 2 to 3% of all paediatric brain tumours. More than 50% occur in the first 5 years of life [44]. PNETs, as medulloblastomas, are classified as embryonal tumours of the central nervous system and histologically correspond to WHO grade IV [45].

The treatment of SPNET is comparable with the one of medulloblastoma, i.e., surgery, chemotherapy, craniospinal irradiation with a localized boost.

Children with SPNET have an even worse prognosis than patients with medulloblastoma because of CSF dissemination and local relapses. Currently, the 5-year survival rate for patients with SPNET is around 31% [46].

The results of several trials are displayed in Table 3. Interestingly, the analysis of the German trials HIT-SK87 and HIT-SK92 shows that avoiding radiation therapy in young children decreases dramatically survival [50], and the analysis of prospective German brain-tumour trials, HIT88, 89, and 91 shows statistically significant loss of local control if doses are less than 54 Gy.

In a curative intent in young children having SPNET and undergoing focal or craniospinal irradiation, a high-dose supratentorial boost is indicated. One could expect from a reduced toxicity by decreasing the dose to normal brain parenchyma thanks to the high dose gradient obtained with proton beams. High precision radiation therapy balance between local control and reduced toxicity suggest the interest, in this rare condition, of a phase II trial.

### 3.3. Ependymoma

Ependymoma accounts for 8 to 10% of paediatric central nervous system tumours, more than half of the cases occur in children younger than 3 years [31,32], and about 2/3 of these tumours locate in the posterior fossa [53,54].

#### 3.3.1. Treatment of ependymoma

Surgery and radiotherapy are the two main treatments for ependymoma. The resections extent is the most important prognostic factor, but the site of the lesions often located in the pontocerebellar region, can limit surgery due to the intimate involvement of the tumour with the lower cranial nerves and the brainstem. Thus, incomplete resection is frequent. Chemotherapy has little effect on this tumour. It is now recommended to perform a second-look surgery if the first one was incomplete [55]. A post-operative irradiation of 59.4 Gy is recommended for all children older than 3 years [37], and tends now to be extended to children as young as 18 months (Table 4).

The overall survival is around 70% at 5 years in case of complete resection, but it is much lower when there is a residue (R2) [56-58]. New radiation techniques have been introduced into childhood ependymoma treatment. As displayed in Table 4, the Massachusetts General Hospital recently reported the outcome for 70 children with localized ependymoma treated with protons [59,60]. At median follow-up of 46 months, local control and survival were excellent, and the complication rate particularly low. The toxicity of radiation therapy on these young children is a true concern [61,62]. Merchant et al. developed a model that combined dose-volume data with clinical factors to predict intelligence quotient outcomes [63]. Their results contain important information of the radiation effects on normal tissues. The analysis showed that the radiation dose remains the most clinically significant determinant of intelligence quotient outcomes, even low doses, less than 20 Gy, in the supratentorial brain receiving only the diffused dose from the infratentorial radiation therapy, have an impact on final intelligence quotient. Further reduction of the brain volume that receives the highest dose is warranted and protontherapy allows

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Number of patients</th>
<th>Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chintagumpala et al., 2009 [47]</td>
<td>– Craniospinal irradiation 23.4-39 Tumour bed 55.8 Gy</td>
<td>16</td>
<td>5-year: 73 % 5-year: 68 %</td>
</tr>
<tr>
<td>Pizer et al., 2006 (PNET 3) [48]</td>
<td>– Craniospinal irradiation 35Gy + boost 20 Gy, 1.67 Gy/fraction</td>
<td>(51 patients) 68</td>
<td>3-year: 54.4 % 5-year: 48.3 % 5-year: 47.0 %</td>
</tr>
<tr>
<td>Hong et al., 2004 (CCG 921) [49]</td>
<td>– Craniospinal irradiation 23.4 Gy-36 Gy + boost 18-21.6 Gy</td>
<td>+</td>
<td>44</td>
</tr>
<tr>
<td>Timmermann et al., 2006 (HIT-SK87, HIT-SK92 trials) [50]</td>
<td>– Craniospinal irradiation 35.2 Gy in 1.6 Gy/fraction, 5 fractions/week + boost 20 Gy in 2 Gy/fraction, 5 fractions/week (15 patients)</td>
<td>+</td>
<td>29</td>
</tr>
</tbody>
</table>
a dramatic reduction of supratentorial brain dose exposure as well as the direct dose to neuerosensory structures.

However, local control remains in the scope of treatment improvements; the possibility to compensate an incomplete surgery by a localized radiation boost with protons is an issue. Actually, in cases of macroscopic postoperative residue, a stereotactic boost of two fractions of 4 Gy has been proposed [64], and will be delivered by protons or protons stereotactic irradiation in the upcoming European prospective trial from SIOP. Whether or not the innovative radiotherapy techniques outperform conformal radiotherapy with better tumour control and neurocognitive outcome will have to be evaluated prospectively with an adequate follow-up. If dose escalation is proposed with protons, the principle of randomization is to be considered.

There is an ongoing protocol in France for re-irradiation of ependymoma local relapses with stereotactic hypofractionated radiotherapy (NCT02013297): https://clinicaltrials.gov/ct2/show/NCT02013297?term=SBRT&rank=1. Depending on the future results of this study, in case of residual failure in “high” dose volume, the question of testing carbon ions could be raised.

If protontherapy is indicated for posterior fossa ependymoma as it can spare dose exposure to supratentorial compartments of the brain and auditory structures, supratentorial ependymomas, which are often large, and occur in children over 10 years of age, could represent also a good indication for protons in order to reduce neurocognitive impairments, as illustrated by Fig. 2 [59].

### 3.3.2. Ongoing study on protontherapy for ependymomas

There is only one ongoing prospective study with protons, including ependymoma, it is the one described in the “low grade glioma” section (NCT01288235): http://clinicaltrials.gov/show/NCT01288235.

### 3.4. Atypical teratoid rhabdoid tumours

The atypical teratoid rhabdoid tumour of the brain was first identified in 1995. It is a very aggressive and rare tumour, occurring mainly in very young children. It accounts for 1.5 to 2.1% of paediatric brain tumours [65]. Meningeal metastatic spread is noted in approximately 1/3 of the atypical teratoid rhabdoid tumour cases at the time of diagnosis.

The treatment principles of atypical teratoid rhabdoid tumour consist of surgery resection followed by a variety of chemotherapy regimens with or without radiation therapy. The median survival time ranges from 6 to 11 months. A multi-institutional phase II clinical trial has been conducted to test the efficacy of an aggressive multimodality approach for children with newly diagnosed atypical teratoid rhabdoid tumour, which associate surgery, radiotherapy and chemotherapy. It has resulted in a significant improvement in the time to progression and for the overall survival: the 1-year overall survival and progression-free survival were 75% and 70% respectively [66].

As life expectancy remains unfortunately short in these patients, avoidance of late toxicity is not yet a priority although one group reports offering protontherapy in respect to the very young age of those patients [67].

The current approach for atypical teratoid rhabdoid tumour is combining high-dose chemotherapy and local or craniospinal irradiation with photons.

### 3.5. Germ-cell tumours

Germ-cell tumours represent 3 to 5% of childhood brain tumours. They arise mainly in midline suprasellar or pineal structures in adolescents [11]. They are usually localized, but they may disseminate. There are two main subtypes: germinomas and tumours with non-germinomatous components.

#### 3.5.1. Pure non-secreting germinomas

Two-thirds of all central nervous system germ-cell tumours are germinomas [68]. Germinoma is highly sensitive to both radiotherapy and chemotherapy, and has an excellent prognosis with an overall survival of 90% at 10 years [69] (Table 5). Indeed, it has long been a standard to treat using craniospinal irradiation only. In order to reduce radiation related toxicity, recent therapeutic
Fig. 2. Radiotherapy of a posterior fossa ependymoma extended to the spine: the dose prescribed was 54 Gy to the tumour bed (lower due to age 2 of the child and tracheotomy) with a boost for a total of 59.4 Gy to the residual tumour and limited dose of 44 Gy to the spine. Note the low dose given to the internal ear (20 Gy) and the absence of dose given to visual structures and the pituitary gland. Courtesy of Dr S. Bolle, centre de proonthérapie d’Orsay.

Table 5
Published studies on the treatment of germ-cell tumours in children.

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Number of patients</th>
<th>Efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Radiotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proton</td>
<td>Photon</td>
<td></td>
</tr>
<tr>
<td>Non-germinomatous germ-cell tumours treated with radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kretschmar et al., 2007 [70]</td>
<td>Neuroaxis: 50.4 Gy local + 30.6 Gy neureaxis in complete response; 54 Gy local + 36 Gy if less than complete response</td>
<td>14</td>
<td>3-year: 79%</td>
</tr>
<tr>
<td>Calaminus et al., 2013 [71]</td>
<td>Focal irradiation 54 Gy</td>
<td>96</td>
<td>2-year: 77%</td>
</tr>
<tr>
<td>M0</td>
<td>Craniospinal irradiation 54 Gy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germinomas treated with radiotherapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kretschmar et al., 2007 [70]</td>
<td>30.6–54 Gy</td>
<td>12</td>
<td>3-year: 100%</td>
</tr>
<tr>
<td>Calaminus et al., 2013 [71]</td>
<td>Craniospinal irradiation 24 Gy + boost 16 Gy</td>
<td>113</td>
<td>NA</td>
</tr>
<tr>
<td>Option A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Option B</td>
<td>Focal irradiation: 40 Gy</td>
<td>57</td>
<td>2-year EFS: 90%</td>
</tr>
<tr>
<td>Bamberg et al., 1999 [69]</td>
<td>Craniospinal irradiation 36 Gy + boost 14 Gy</td>
<td>60</td>
<td>5-year EFS: 93.7%</td>
</tr>
<tr>
<td></td>
<td>Craniospinal irradiation 30 Gy + boost 15 Gy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bouffet et al., 1999 [72]</td>
<td>40 Gy, craniospinal irradiation, 25–30 Gy in case of disseminated germinoma</td>
<td>57</td>
<td>3-year: 98%</td>
</tr>
</tbody>
</table>

PFS: progression-free survival; EFS: event-free survival.
practice of localized germinomas has used a combined approach with chemotherapy followed by radiation therapy limited to the tumour bed, which has led to good survival [71]. However, a specific pattern of relapse has been observed within ventricles, with no or a very low rate of craniospinal relapse [70,72,73]. Thus, an approach with whole ventricular radiation therapy, plus a localized boost, has been suggested and could yield an equivalent survival with an expected reduced long-term toxicity [74].

Actually, although general cognitive abilities appeared stable and intact after treatment for most children with central nervous system germ-cell tumours, a significant decline over time in working memory, processing speed, and visual memory was observed in a study of longitudinal evaluation of neurocognitive function after treatment for 35 germ-cell tumours [75]. After examination of the impact of radiation field, Mabbott et al. found that patients treated with craniospinal irradiation performed poorly, relative to those treated with ventricular volumes, on measures of intellectual function, reading, and receptive vocabulary. However, the location of the tumour was also predictive of the extent of detriment. These results suggest that attempts at reducing radiation volumes in patients with central nervous system germ-cell tumours and in particular patients with germinoma are supported by long-term differences cognitive outcomes [75].

However, the coverage of such a complex shape, as the whole ventricles, means that a significant volume of the brain receives a significant dose of radiation therapy [76]. A recent retrospective study from Massachusetts General Hospital described the outcome for 22 children with protontherapy where 100% local control was achieved. Substantial normal-tissue sparing was seen when intensity-modulated radiation therapy was compared to the different proton treatments: i.e. conformal protontherapy (passive scattering or scanning), or intensity modulated protontherapy. This latter technique allowed additional sparing [77,78].

Recommendations
Given the excellent survival rates in both localized and metastatic conditions with, respectively, localized and craniospinal irradiation, we would recommend that all patients should benefit from proton therapy, or at least the younger ones, i.e. less than 12 years of age.

In SIOP studies, germinoma with a teratoma component receive whole ventricular irradiation followed by a higher 54 Gy total dose to the primary if incomplete surgery.

3.5.2. Non-germinomatous germ-cell tumours
Non-germinomatous germ-cell tumours occur in younger patients around 10 years of age, it is an heterogeneous entity with frequently several components combining choriocarcinoma, yolk-sac tumour, embryonic carcinoma with survival rates at 5 years around 60% [14,68,73,79]. Postoperative residue together with elevated AFP markers is of prognostic value.

3.5.3. Ongoing studies on the treatment of germ-cell tumours
A European prospective non randomized trial for the diagnosis and treatment of children, adolescents and adults with intracranial germ-cell tumours, is opening in most French centres: SIOP CNS GCT II, http://clinicaltrials.gov/ct2/show/NCT01424839?term=germ+cell+tumours&recr=Open+&intr=radiotherapy&rank=1. For localised germinoma, patients receive primary chemotherapy followed by radiation treatment to whole ventricular system up to 24 Gy. Only in cases with non-complete response to chemotherapy after centralized review, an additional boost of 16 Gy bringing total dose to 40 Gy is delivered to the primary site. For metastatic germinoma, a craniospinal irradiation at 24 Gy followed by a boost of 16 Gy (total dose 40 Gy) is delivered. For non-germinomatous malignant germ-cell tumours: if localized, 54 Gy are delivered to the primary site, if metastatic, a craniospinal irradiation of 30 Gy plus a boost of 24 Gy (total dose 54 Gy) to primary site and intracranial metastases is delivered, and a boost of 20 Gy for spinal metastases.

A specific protontherapy study is ongoing at the Massachusetts General Hospital: phase II study of proton radiation therapy for central nervous system germ cell tumours: evaluation of acute and late side effects (NCT01049230), delivering local, ventricular or craniospinal protontherapy.

3.6. Craniopharyngioma

Craniopharyngioma is the third most common intracranial tumour in children, with the majority of cases occurring between 5 and 14 years of age. This histologically benign tumour of epithelial origin is located, in 70% of cases, in the retrochiasmatic region, often extending into the third ventricle, along the hypothalamus, close to cerebral arteries, optic tracks, the pituitary gland, the hippocampal formation, and cranial nerves. Therefore, its insidious growth can cause severe damages and can even be, at last, life threatening. In addition, its localization is very challenging for safe radiotherapy delivery. Obesity, one of the most deleterious side-effects of therapy is purely attributable to surgery.

3.6.1. Published studies on the treatment of craniopharyngiomas

According to the presentation, two treatment options are proposed: either primary total resection or, particularly in case of hypothalamic involvement, conservative limited surgery followed by external-beam irradiation.

The relapse rate for surgery alone is approximately 20 to 70%, depending on the extent of the resection. Radiation therapy, after subtotal resection, improves the local control rate at 10 years to approximately 80 to 85% [80,81]. Habrand et al. reported, in 1999, very encouraging results from 25 years of experience in children treated with radiation therapy by using conformal radiation therapy combined or not with surgical resection at a single institution. The 5-year overall survival rate was 90% using doses between 45 and 56 Gy [81].

As craniopharyngioma is a benign tumour, a stereotactic radiation therapy approach is warranted when it is small in volume. However, as it is often located close to the optic pathways, a fractionated treatment maybe more adequate than radiosurgery [82,83]. Indeed, in a study of 21 patients (11 children and 10 adults) treated by radiosurgeries, Ulfansson et al. described 38% visual complications and 63% of relapses [84]. Merchant et al. published, in 2006, the results of a phase II trial with conformal radiation therapy using photons, which had excellent local control, and concluded that the security margins could be safely reduced from 20 mm to 10 mm (nowadays, standard margins vary from 3 to 5 mm), while significantly decreasing radiation doses to the brain and, therefore, improving probability of intelligence quotient preservation [85]. The percentage of total brain, supratentorial brain, or left temporal lobe volumes receiving a dose in excess of 45 Gy had a significant impact on longitudinal intelligence quotient. More recently, a series, with doses ranging from 50 to 55 Gy of protons, gave local control for 14 out of 15 patients with no later adverse visual effects [86]. Another series of preliminary results of 15 patients (5 children and 10 adults, median age of 36 years) from Massachusetts General Hospital, with mixed photon and proton beams, and a median dose of 56 Gy (IsoE), described a 93% 5-year local-control rate [87]. A recent work from the MD Anderson Cancer Center compared tumour coverage and doses to organs at risk in 10 paediatric patients with
Table 6
Published studies on the treatment of craniopharyngiomas in children.

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Number of patients</th>
<th>Efficacy</th>
<th>Overall survival</th>
<th>Progression-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merchant et al., 2006 [85]</td>
<td>– Conformal radiotherapy: 54–55.8 Gy, 1.8 Gy/fraction</td>
<td>28</td>
<td>NA</td>
<td>3-year: 90.3%</td>
<td></td>
</tr>
<tr>
<td>Amendola et al., 2003 [89]</td>
<td>– Gamma knife radiosurgery Mean dose max 14 Gy (11–20 Gy) Mean dose max 29 Gy (24–40 Gy)</td>
<td>14</td>
<td>100% (mean follow-up 39 months)</td>
<td>Local control: 12/14 (mean follow-up 39 months)</td>
<td></td>
</tr>
<tr>
<td>Minniti et al., 2007 [82]</td>
<td>– Stereotactic conformal radiotherapy: 50–55 Gy, 30–33 fractions in 6–6.5 weeks</td>
<td>39</td>
<td>3-year: 100 % 5-year: 100 %</td>
<td>3-year: 97 % 5-year: 92 %</td>
<td></td>
</tr>
<tr>
<td>Luu et al., 2006 [86]</td>
<td>Proton beam radiotherapy: 50.4–59.4 CGE, 1.8 CGE/fraction, 5 fractions/week</td>
<td>16</td>
<td>12/15 (mean follow-up 60.2 months)</td>
<td>Local control: 14/15 (mean follow-up 60.2 months)</td>
<td></td>
</tr>
</tbody>
</table>

CGE: cobalt gray equivalent.

3.6.2. Ongoing studies on the treatment of craniopharyngioma


The goal of this study is to determine the feasibility and safety of a limited surgery and a 5-mm clinical target volume margin in combination with proton therapy when surgery is incomplete (R2). The primary outcome measures are progression-free survival and overall survival.

An ongoing French phase II study driven at Curie Paris Orsay institute evaluates the feasibility of increasing the dose up to 59.5 Gy with respect of dose constraint to the optic pathway, with proton therapy after incomplete conservative surgery.

3.7. Toxicity studies

Below is a synthesis of the main benefits expected on the following organs at risk.

3.7.1. Brain

Cognitive impairments due to radiotherapy may be lowered by the significant decrease of dose around the target volume [86].

3.7.2. Pituitary gland

Hormonal deficiency is very common after brain tumour irradiation as growth hormone deficiency occurs very frequently above a dose of 18 Gy and thyroid stimulating hormone and adrenocorticotropic hormone deregulations above 40 Gy. Proton therapy reduces significantly the dose to the pituitary gland, avoiding unnecessary irradiation [59].

3.7.3. Auditory structures

Auditory structures are very sensitive as a median dose of 35 Gy represents a high risk for auditory deficit. Irradiation of the posterior fossa, the most frequent site of paediatric brain tumours, at doses of 50 to 60 Gy, elicits high doses to these structures, even with intensity-modulated radiation therapy; proton therapy allows a much better protection [63].

3.7.4. Visual structures

As an example, the use of protons allows to deliver 59 Gy in residual craniopharyngiomas while preserving chiasm, as evaluated in the current French prospective protocol described above [86].

3.7.5. Brainstem

A comparative study in infratentorial ependymoma showed a significant decrease of dose on brainstem [59]. This may be very beneficial for these tumours often situated in the pontocerebellar angle; as a reduction in dose due to brainstem constraints would not be necessary anymore with protons.

3.7.6. Late effects of proton therapy

Better information about late effects has to be obtained through prospective studies especially carried out for such assessment. Through open paediatric protocols for patients treated with proton therapy, the investigators of the following clinical studies aim

3.6. craniopharyngioma treated with intensity-modulated radiation therapy. 3D-protontherapy, or intensity-modulated protonotherapy [88]. A significant reduction in dose to the hippocampal (−51.3%) and vascular structures was obtained with protontherapy (Table 6).
to define and report the acute and late effects associated with treatment:

- outcomes study of late effects after proton radiotherapy for paediatric tumours of the brain, head, and neck (CN01, Florida, NCT01067196);
- neurobehavioural functioning in paediatric brain tumour patients after proton beam radiation treatment (Massachusetts General Hospital, NCT01180881);
- proton radiotherapy for paediatric brain tumours requiring partial brain irradiation (Massachusetts General Hospital, NCT01288235);
- prospective assessment of quality of life in paediatric patients treated with radiation therapy for brain tumours and non-central nervous system malignancies.

3.8. Second cancers

Another side effect that should be reduced with proton therapy is second cancers, the potential influence of improved dose-distribution with protontherapy was evaluated on a dosimetric study of paediatric medulloblastoma: the incidence of second cancers was expected to be reduced by a factor 5 to 8 [92]. A review by Hall underlined that “The benefit of protons could be achieved if a scanning beam was used in which the doses are 10 times lower than with intensity-modulated radiation therapy” [94]. A more recent retrospective study on 558 patients, among whom 44 paediatric cases, reports a second cancer rate of 5.2% for adult proton patients versus 7.5% for adult photon patients and none in paediatric patients but the follow-up of the whole cohort was short (6.7 years), and patients had been mainly treated with passive scattering method [95]. Further specific paediatric studies are needed with a more detailed analysis of the site of second cancers compared to the first cancer treatment site, when using scanning proton beam.

3.9. Cost-effectiveness of protontherapy in a paediatric setting

The base-case study using a Markov cohort-simulation model by Lundkvist et al. showed that protontherapy applied in medulloblastoma was associated with € 23,600 in cost savings and 0.68 additional quality-adjusted life-years per patient [96]. Interestingly, the analyses showed that this achievement was mainly obtained through the reduction of late toxicity. Actually, reductions in intelligence quotient loss and growth hormone deficiency contributed to the greatest part of the cost savings and were the most important parameters for cost-effectiveness. This type of study shows which improvement could be expected from a larger use of protontherapy when toxicity issues are the main concern.

3.10. Results of the indications recommended by the group of paediatric radiation oncology

The literature analysis is in favour of the use of proton therapy for paediatric brain tumour in a curative intent, either for focal irradiation (localized ependymoma; germ-cell tumours; craniohypophysemia; low-grade glioma), whole-ventricular irradiation (germinoma), or craniospinal irradiation (medulloblastoma, disseminated germ-cell tumours). Therefore, the eligible population in France would represent approximately 300 children and 100 adolescents and young adults each year.

4. Discussion

Paediatric radiotherapy is often considered as a two-edged weapon. On one edge, a necessary and efficient treatment for children’s solid tumour, particularly brain tumours, on the other edge, a source of mild to severe late effects: cognitive, endocrinial, auditory and visual. In the everyday practice of paediatric radiation oncology, the question of referral to a protontherapy centre is frequent but resources are scarce and no national guidelines exist for paediatric brain tumour. This prompted us to analyse literature for hadrontherapy indications in children in order to make recommendations and evaluate the number of children that would benefit from a protontherapy treatment in France. We have detailed above for each tumour type the benefit expected from protontherapy as well as discussed cost-effectiveness.

Carbon ions therapy is just emerging in adults and has not been yet applied to very young patients. However, benefit for high-grade glioma or diffuse intrinsic pontine glioma might be questioned as primary care or treatment at relapse.

Concerning protontherapy, literature data is in favour of neurocognitive, sensorial and endocrine benefits with protons compared to photons for all paediatric patients treated for brain tumours in a curative intent. Actually, the physics of protontherapy allow outstanding ballistics to target the tumour area, while substantially decreasing radiation dose to the surrounding normal tissues. Results from this literature analysis are in favour of decreased late effects without drawback on survival. The literature analysis is in favour of the use of proton therapy for paediatric brain tumour in a curative intent, either for focal irradiation, whole-ventricular irradiation, or craniospinal irradiation. We analysed carefully the incidence of all brain tumours within the children and adolescents and young adults population in France published by Sommelet et al., Lacour et al. and Désandes et al. [97–99]. The eligible population in France, following our recommendations, for conventional dose protontherapy in a curative setting represents 315 children and 95 adolescents and young adults per year, reaching 410 patients per year.

Many ongoing prospective clinical trials will allow evaluating the efficacy and toxicity of protontherapy. With increasing medical imaging tumour evaluation, one can also suggest that protontherapy could be also used for dose-escalation on resistant tumours, without increased healthy tissue irradiation. An elegant approach could be dose-painting, i.e. increasing dose to radioresistant clusters identified by molecular imaging [100,101]. The paediatric ependymoma photons protons and imaging (PEPPi) study is currently driven by the Pélicés team in collaboration with France Hadron and the radiotherapy committee of the French society of paediatric oncology. This retrospective study analyses all anatomic and metabolic imaging, as well as treatment plans of 227 paediatric patients with a newly diagnosed ependymoma treated in the French paediatric radiotherapy reference centres [102]. The aim of this study is to define new biological target volumes [103] and perform multicentric in silico dose painting dosimetric studies comparing photons and protons with the ambition of a future dose-painting proton prospective trial.

5. Conclusion

In France, 600 children every year receive a radiotherapy and brain tumours radiation therapy is the most frequent indication. To this, we can add the adolescents and young adults population. The number of indications for protons for a curative setting in paediatric and adolescents and young adults with brain tumours is 410 per year. Therefore, the need for protontherapy for such internationally acknowledged development, added to the other recognized and reimbursed indications (other paediatric and young adults cancers, ocular melanomas, base of skull, spinal and paraspinal tumours, low grade sarcomas, selected head and neck carcinomas) is not covered by the single existing protontherapy facility in France at
Orsay and will not be covered by the additional upcoming faculty, in Nice. Additional protontherapy centres with children-dedicated equipment are needed to offer equal access to this therapy. These centres should include general anaesthesia capacity, trained team and could be cost-efficient.

Disclosure of interest

The authors declare that they have no competing interest.

References


